BPC-157 vs TB-500: how the two peptides differ

What is the difference between BPC-157 and TB-500?

BPC-157 and TB-500 differ in size, origin and research record. BPC-157 is a synthetic peptide of 15 amino acids, GEPPPGKPADDAGLV, that matches a fragment of a protein reported in human gastric juice (Sikirić et al., 1993). TB-500 is a synthetic fragment of seven amino acids, positions 17 to 23 (LKKTETQ), of the 43-amino-acid protein thymosin beta-4, with an acetyl group on its first amino acid (FDA, July 2026; Low et al., 1981). In its TB-500 evaluation dated 15 May 2026, the FDA says TB-500 is a common name and not a United States Adopted Name, and that multiple salts and derivatives, including different active moieties, are sold commercially under it.

TB-500 entered the literature through sport. A 2012 paper describes it as a veterinary preparation whose key ingredient is the acetylated LKKTETQ peptide, and its authors built a test to detect it in horse urine and plasma (Ho et al., Journal of Chromatography A, 2012). A doping-control laboratory identified the same acetylated fragment in a product suspected of doping use (Esposito et al., Drug Testing and Analysis, 2012).

BPC-157 comes from a different line of work. It was developed in Zagreb as a stable fragment of a gastric-juice protein and studied mainly for gut, tendon and muscle injury in rats (Sikirić et al., 1993; Mateescu et al., 2026).

Which is better supported by studies, BPC-157 or TB-500?

The FDA briefings and PubMed records searched on 14 October 2026 did not identify a comparison in people. The FDA identified five small BPC-157 studies of 2 to 53 people each, with limited reporting, and no TB-500 clinical studies (FDA, July 2026). In 32 rats with repaired Achilles tendons, four per group analysed for each endpoint, the material labelled TB-500 reached significance on breaking load and tissue scores, BPC-157 did not on total tissue scores, and the combination added no benefit, an exploratory animal result that does not rank the peptides for people or independently confirm the TB-500 material's identity (Biçer et al., Joint Diseases and Related Surgery, 2026).

The rat study's authors called the work exploratory (Biçer et al., 2026). A scoping review of six peptides, including BPC-157 and TB-500, describes the human evidence as heterogeneous and mostly lacking robust controls (Tewari et al., American Journal of Sports Medicine, 2026).

The two peptides have different gaps. For BPC-157, 35 of the 36 studies in a 2025 systematic review were preclinical (Vasireddi et al., 2025). For TB-500, the FDA's evaluation did not identify nonclinical in vivo studies assessing wound healing, or any human studies (FDA, July 2026).

How much animal evidence exists for each peptide?

The identified evidence sets differ. A systematic review included 35 preclinical BPC-157 studies, a selected set searched to 3 June 2024 (Vasireddi et al., HSS Journal, 2025). The FDA evaluation dated 15 May 2026 identified no living-animal TB-500 wound-healing study within its search (FDA, July 2026). In a cultured-fibroblast scratch assay, with no sample count in the FDA summary, TB-500 wound closure did not significantly differ from vehicle, a cell result that does not establish a human result (FDA, July 2026). In 32 rats, four per group analysed mechanically, material labelled TB-500 had a higher breaking load than control, an exploratory animal result that does not establish a human result or independently confirm molecular identity (Biçer et al., 2026).

Thymosin beta-4 and its fragments are distinct molecules. In 26-month-old mice, with no group size in the FDA summary, an unacetylated seven-amino-acid fragment increased epidermal closure, an animal result that does not establish a human result and cannot be directly extrapolated to acetylated TB-500 (FDA, July 2026).

The full study results for BPC-157 are set out on the study findings page.

Have BPC-157 and TB-500 been studied together?

The FDA briefings and PubMed records searched on 14 October 2026 identified one controlled comparison. In 32 rats with repaired Achilles tendons, four per group analysed for each endpoint, combined BPC-157 and material labelled TB-500 conferred no additional benefit, an exploratory animal result that does not establish a human result or independently confirm the TB-500 material's identity (Biçer et al., Joint Diseases and Related Surgery, 2026). In a retrospective uncontrolled knee chart review, four of 16 contacted patients had combined exposure, too few to compare with the 12 in the BPC-157-only subgroup (Lee and Padgett, 2021). Two FDA food-complaint reports concerned blended products without safety assessments or proof of cause (FDA, July 2026).

Blended products raise a separate problem, because a reaction cannot be assigned to either ingredient. One of the three FDA reports for BPC-157 involved a 40-year-old woman who reported darkened skin and gums after a product containing both peptides, and the FDA said it could not assess a relationship to BPC-157 because the product contained two peptides (FDA, July 2026).

Is MOTS-c the same as BPC-157?

No. MOTS-c is a different peptide with a different origin and research record. It has 16 amino acids and is encoded in the 12S rRNA gene of mitochondrial DNA, and a 2015 paper reported that, in mice, with group sizes not given in the abstract, treatment prevented high-fat-diet-induced insulin resistance and diet-induced obesity, a mouse finding that is not a human result (Lee et al., Cell Metabolism, 2015). BPC-157 has 15 amino acids, matches a gastric-juice protein fragment, and has been studied mainly in injury models. The FDA's page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, says the FDA has not identified human exposure data on MOTs-C drug products by any route (FDA, April 2026), and the WADA 2026 list names MOTS-c under S4.4.1, activators of AMP-activated protein kinase (WADA, 2026).

A 2026 review of peptides marketed in sports medicine covers BPC-157, TB-500 and MOTS-c among 12 peptides and states that rigorous human safety data for the unapproved peptides are scarce (Mendias and Awan, Sports Medicine, 2026).

What do studies show about BPC-157 in women?

The FDA briefing and PubMed records searched on 14 October 2026 did not find a BPC-157 study that analysed results by sex, so they cannot say how results differ for women. The one human report built on women, a 2024 pilot, enrolled 12 women aged 39 to 76 with interstitial cystitis, a bladder-pain condition, and reported no adverse events and a top score on a patient-rated questionnaire, with no control group (Lee et al., Alternative Therapies in Health and Medicine, 2024). The FDA review identified pregnancy-related data only in a rat toxicity study, with no group size in its summary and no basis to establish a human result (Xu et al., Regulatory Toxicology and Pharmacology, 2020; FDA, July 2026). The side effects page covers women, men and pregnancy in more detail.

Two of the three BPC-157 reports in the FDA's adverse-event database came from women, and the FDA could not say that BPC-157 caused them (FDA, July 2026). A small number of reports says nothing about how common any problem is in women.

What do studies say about how quickly BPC-157 acts?

The FDA briefing and PubMed records searched on 14 October 2026 did not find a study that timed it in people. The rat experiments recorded healing over days to weeks, assessed up to day 14 for a cut Achilles tendon and across a 72-day period for a cut quadriceps muscle, with group sizes not given in the abstracts, and a time seen in a rat does not carry over to a person (Staresinic et al., 2003 and 2006). The human report, a retrospective uncontrolled chart review of 17 knee patients in which 16 were contacted months later, was not built to measure onset (Lee and Padgett, 2021).

The FDA's July 2026 briefing states that it found no information to assess human BPC-157 pharmacokinetics. Clearance from blood and the timing of a tissue effect are separate questions; the FDA review establishes neither for people (FDA, July 2026).

What do studies show about BPC-157 and gut healing time?

The FDA briefing and PubMed records searched on 14 October 2026 did not find a study that timed gut healing in people. In rats with a persistent colon-to-skin fistula, healing was checked on days 1 to 28 after surgery, and BPC-157 was reported to speed closure of the colon and skin defects, in a rat model with a group size not given in the abstract that does not show the same in people (Klicek et al., Journal of Pharmacological Sciences, 2008). In rats with a temporarily blocked colon blood supply, the authors reported more visible vessels in BPC-157-treated colon segments within 15 minutes, and in rats whose colon was also obstructed, almost completely spared mucosa on day 10, again in rats only and with group sizes not given in the abstract (Duzel et al., World Journal of Gastroenterology, 2017). The randomised human colitis study the FDA identified, a 2005 meeting abstract in 53 adults with ulcerative colitis that the FDA judged inadequate, reported a between-group difference whose 95% confidence interval included no difference (Ruenzi et al., 2005, via FDA, July 2026).

Those rat models are surgical injuries, and they are not the same as everyday gut complaints. Whether a rat result applies to people with bowel disease is the question the colitis abstract tried to answer, and the FDA called its data inadequate (FDA, July 2026).

How do regulators and sport treat BPC-157, TB-500 and MOTS-c?

The sources read on 14 October 2026 list no approved medicine containing any of the three. The FDA page on bulk drug substances that may present significant safety risks, current as of 22 April 2026, names all three, and for TB-500 and MOTS-c it says the FDA has not identified human exposure data (FDA, April 2026). The World Anti-Doping Agency's 2026 list names all three as prohibited at all times, with BPC-157 under S0, TB-500 under S2.3 as a thymosin beta-4 derivative, and MOTS-c under S4.4.1 (WADA, 2026). The TGA's 13 April 2026 advisory names BPC-157 and TB-500 among unapproved peptide products (TGA, 13 April 2026).

These are three separate systems with three separate rules, and a sport ban says nothing about safety or about legal status. How the Poisons Standard applies is set out in BPC-157 and the Poisons Standard.

Does the name on a research-material label match the peptide in a study?

A name on a label cannot say. The FDA wrote that TB-500 is a common name, that salts and derivatives with different active moieties are sold under it, and that inconsistent naming is itself a safety risk (FDA, July 2026). For BPC-157, the FDA wrote that it is not well characterised from a physicochemical perspective (FDA, July 2026). So no sample can be assumed to match what any study tested. Research-use reference material is a laboratory compound, not a medicine, not a substitute for one and not for human or animal use.

The catalogue lists BPC-157 reference material as laboratory stock, and a catalogue entry is not evidence about any study. The quality and verification hub explains what a certificate of analysis can and cannot show.